New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays

SUNNYVALE, Calif., Sept. 28 /PRNewswire/ -- Molecular Devices, Inc., a leader in bioanalytical systems for drug discovery & development, life science research, and bioassay/test development, today announced that it is taking orders for its new IonWorks Barracuda™ Automated Patch Clamp System.

(Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100406/SF82092LOGO)

Following the tradition of IonWorks® Systems before it, this new system delivers the highest throughput for automated electrophysiology analysis available at the lowest cost per data point. It also incorporates the patent-pending Population Patch Clamp™ (PPC) Recording Technology that revolutionized ion channel screening and has become the standard for directed library and hit-to-lead applications.

The IonWorks Barracuda System can screen both voltage-gated and rapidly-desensitizing ligand-gated ion channels due to the unique design of the Patch Plate Consumable and an electrode plate that enables researchers to add compound while recording. In addition, the system can generate more than 1,100 data points per hour as a result of being able to add compounds and record from 384-wells simultaneously.  

Measuring from 384 wells in parallel means that researchers can now complete a screening experiment in as little as 20 minutes, making the new IonWorks Barracuda System the technology of choice for drug discovery programs focused on ion channel targets. No other system on the market today can provide the same combination of throughput and low cost per data point for screening large, directed compound libraries against ion channel targets via direct electrophysiology assays. Because of the low running costs of IonWorks platforms the system can pay for itself in as few as three directed library screens compared to other automated electrophysiology platforms. The system is also well suited for follow-on studies, such as hit-to-lead, compound profiling, and safety assessments.

"This System is the ideal screening solution for cardiovascular, metabolic, central nervous system, and immune function drug discovery programs," said Mark Verheyden, President of Molecular Devices. "Ion channels have long been implicated in these disorders, yet they remain a largely unexplored target class due to a historical lack of practical technologies that provided the required throughput. Now, with the IonWorks Barracuda Platform, drug discovery researchers can screen large, directed libraries against both types of ion channels via direct electrophysiology assays affordably, giving them the technology they need to discover new chemical entities that could one day be used to improve the lives of people afflicted with these debilitating disorders."

About Molecular Devices: At Molecular Devices we have one focus—our customers. When you become our customer, your needs drive our actions and your success is our concern. Our instruments offer a full spectrum of detection technologies and meet all throughput and content needs. Our goal is to deliver highly relevant bioanalytical products to detect biology, decode data, and drive discovery.

Global Sales & Support Offices: N America: 1 800 635 5577, Brazil: +55 11 3616 6607; UK: +44 118 944 8000; Germany: +49 89/96 05 88 0; China: +86 10 6410 8669 (Beijing), +86 21 6887 8820 (Shanghai); Japan: +81 6 6399 8211 (Osaka), +81 3 5282 5261 (Tokyo); S Korea: +82 2 3471 9531

All products are FOR RESEARCH USE ONLY. Not for Use in Diagnostic Procedures.

All trademarks are the property of Molecular Devices, Inc.

SOURCE Molecular Devices, Inc.